|
|
Volumn 8, Issue 1, 2012, Pages 1-
|
|
Pharmacotherapy: Vandetanib - A new therapeutic option in advanced medullary thyroid cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PLACEBO;
PROTEIN TYROSINE KINASE INHIBITOR;
VANDETANIB;
ADULT;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
DRUG APPROVAL;
DRUG EFFICACY;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
HUMAN;
MAJOR CLINICAL STUDY;
NOTE;
OVERALL SURVIVAL;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
THYROID CANCER;
THYROID MEDULLARY CARCINOMA;
TREATMENT RESPONSE;
FEMALE;
HUMANS;
MALE;
PIPERIDINES;
QUINAZOLINES;
THYROID NEOPLASMS;
|
|
EID: 83555176012
PISSN: 17595029
EISSN: 17595037
Source Type: Journal
DOI: 10.1038/nrendo.2011.198 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
